Takeda Launches Combined Actos/Nesina Diabetes Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical launched a combination diabetes drug that combines its blockbuster Actos (piaglitizone) drug facing loss of patent protection, with Nesina (alogliptin)